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Introduction. The incidence of gastric remnant carcinoma does not decrease after partial gastrectomy. The aim of this study
was to evaluate the clinical features and prognosis of gastric remnant carcinoma after treatment. Methods. Among 412 gastric
carcinoma patients who were admitted to our hospital, 21 were found to have gastric remnant carcinoma. We analyzed their
clinicopathological features and prognosis. Results. Prognosis did not diﬀer signiﬁcantly in terms of gender, age, tumor lymph
node metastasis stage, tumor location, and time interval between ﬁrst and subsequent operations. However, it was inﬂuenced by
intensive curative gastrectomy with resection of local lymph nodes. Conclusion. Long-term follow-up after gastrectomy, appro-
priate curative resection, and prevention and management of comorbidities are important to detect gastric remnant carcinoma at
an early stage.
1.Introduction
Balfour was the ﬁrst to demonstrate the existence of gastric
remnant carcinoma that occurred more than 5 years after
partialgastrectomyforbenigngastriculcerdisease.Although
proton-pump inhibitor therapy and therapeutic endoscopy
are currently being performed instead of partial gastrectomy
for bleeding peptic ulcers, the incidence of gastric remnant
carcinoma is not decreasing. This malignancy has also been
described in patients who have undergone gastric bypass
surgery for obesity. The causes for remnant carcinoma possi-
blyinvolvegastroduodenalreﬂuxofbileandpancreaticjuice,
denervation during gastrectomy with hypochlorhydria, and
al o n gl a t e n c yp e r i o d .Helicobacter pylori infection is not an
important factor in this case [1, 2].
Many studies have shown diﬀerences between the clin-
icopathological features of gastric remnant carcinoma and
patient outcomes after partial gastrectomy for peptic ulcer
complications [3–5] .T h ea i mo ft h i ss t u d yw a st oe v a l u a t e
the clinical features and prognosis of gastric remnant carci-
noma after treatment.
2. Patients andMethods
BetweenJanuary2004andNovember2008,412patientswith
gastric carcinoma were admitted to our hospital. Among
them,21wereshowntohavegastricremnantcarcinomaafter
partialgastrectomyforpepticulcers.Thegenderdistribution
inthisstudywas15menand6women.Theaverageageatthe
time of diagnosis was 66.2 years (45–85 years). All patients
underwent abdominal computed tomography for staging or
surgical evaluation. Age, gender, time interval between initial
gastrectomy and diagnosis of cancer, and chief presentation
symptoms at admission were obtained from charts of the
patients. The survival time was estimated on the basis of
evaluation in the ﬁrst year and followed up for 4 years. The
tumors were classiﬁed by site as stump, nonstump, or diﬀuse
remnant and staged using the tumor lymph node metastasis
(TNM)classiﬁcationafterabdominalcomputedtomography
with or without the surgical ﬁndings. All procedures were
performed under the supervision of the hospital ethics com-
mittee.2 ISRN Gastroenterology
Table 1: Presenting symptoms of the 21 patients with gastric remnant carcinoma.
Symptoms Patients
Epigastric pain/fullness 9
Tarry stools/hematemesis 5
Poor appetite 4
Vomiting 3
Table 2: Clinicopathological features of the 9 patients with gastric remnant carcinoma who survived for over 2 years.
No. Gender Age
(years)
Interval
(months) TNM staging Anastomotic
site† Comorbidity Previous
surgery
Prognosis
(years)
1 F 71 30 T1N3M0 + Total gastrectomy Billroth II >4
2 F 52 20 T1N0M0 + Total gastrectomy Billroth II >2
3 M 63 40 T1N0M0 + Total gastrectomy Billroth I >2
4 M 72 16 T1N0M0 + Total gastrectomy Billroth II >2
5 M 73 20 T1N1M0 + Total gastrectomy Billroth II >2
6 M 67 32 T1N1M0 + Chemotherapy Billroth II >2
7 F 62 40 T1N1M0 + Total gastrectomy Billroth II >2
8 M 45 20 T1N1M0 + Total gastrectomy Billroth II >2
9 M 80 50 T1N1M0 + Total gastrectomy Billroth II >3
†Abbreviation: TNM: tumor lymph node metastasis.
Statistical analysis was performed using Fisher’s exact
test. P<0.05 was considered statistically signiﬁcant.
3. Results
Among the 21 patients, only 2 had undergone Billroth I
gastrectomy. The mean interval between the ﬁrst surgery and
diagnosis of remnant gastric carcinoma was 30.5 years (12–
55 years). The presented symptoms were epigastric pain and
fullness, followed in order by tarry stools or hematemesis,
vomiting, and poor appetite (Table 1).
Nine patients survived for over 2 years; 8 had undergone
total gastrectomy with or without lymph node resection,
and 1 had been treated with chemotherapy (5-ﬂuorouracil).
Tumors in all these patients were located at the remnant of
the gastric tract (Table 2). The mean tumor size was 3.5 ±
2.0cm. Among the 12 patients who survived for less than
a year, resection of lymph nodes was not performed and
distant metastasis was not observed, or in some case, they
had comorbidities such as cardiovascular disease (4 patients
had unstable hypertension, myocardial ischemia arrhythmia,
uremia, or cerebral stroke). The tumors were located at the
remnant site in 7 patients, at the nonremnant site in 2, and
at a distant site in 3 (Table 3); the mean tumor size was 4.5 ±
3.0cm.
Survival time did not diﬀer signiﬁcantly in terms of gen-
der, age, TNM stage, tumor location, or time interval be-
tween initial and subsequent operations (P>0.05). The only
factor that inﬂuenced survival was intensive curative gastrec-
tomy with resection of local lymph nodes, as illustrated in
Tables 2 and 3.
4. Discussion
The incidence of gastric remnant carcinoma after sub-total
gastrectomy, especially via the Billroth I operation, varies
from 0.4% to 5%, and the cumulative risk correlates with
increased incidence 15 years after the operation. The overall
5-year disease-free survival is reportedly between 7% and
20%. A low incidence of gastric remnant carcinoma was ob-
served in the Billroth I operation, and a remnant carcinoma
was rarely observed with distal gastrectomy with Roux-en-
Yo p e r a t i v e s[ 6, 7]. This leads to the possibility that gastric
remnant carcinoma may be induced by an exposure of
the lower duodenal contents. Recent reports [8–10]h a v e
revealed that the average interval between initial gastrectomy
and diagnosis of remnant cancer is usually more than 20
years, which is similar to the interval in our study. At present,
there is no consensus regarding the time to begin surveil-
lance, although annual upper gastrointestinal endoscopic ex-
aminations have been suggested [11].
Most patients with gastric remnant carcinoma are diag-
nosed during the symptomatic period with the cancer in
the advanced stages, when the resectability rate is low and
increased risk of comorbidities is present, as in the 4 patients
with cardiovascular disease in our study. This emphasizes the
importance of early diagnosis of gastric remnant carcinoma.
Tumor location at the remnant site is possibly a prognostic
factor; however, the variables between operated and unoper-
atedpatientsinourstudywerenotsigniﬁcantlyrelatedtothe
tumor location (P>0.05), which is similar to that reported
by Firat et al. [6] The ability to perform curative resection
appears to be an important prognostic factor [12]b e c u s e
even after intensive radical gastrectomy, the patients had a
favorable prognosis and good quality of life.ISRN Gastroenterology 3
Table 3: Clinicopathological features of the 12 patients with gastric remnant carcinoma who survived for less than a year.
No. Gender Age
(years)
Interval
(months) TNM staging Anastomotic
site† Comorbidity Previous
surgery
Prognosis
(months)
1 M 73 35 T1N3M0 HCC Billroth II 6
2 M 55 28 T1N0M1 + Liver metastasis Billroth II 10
3 M 80 55 T1N0M1 + Intestinal metastasis Billroth II 5
4 M 50 20 T1N1M0 + LN metastasis Billroth II 11
5 M 48 15 T1N1M1 + Liver and LN metastases Billroth II 4
6 F 60 30 T1N0M2 − Pulmonary and cervical
metastases Billroth II 3
7 M 83 42 T1N0M0 + Uremia on dialysis and
hypertension Billroth II 1
8 F 68 43 T1N1M0 − LN metastasis (bypass) Billroth II 2
9 M 77 16 T1N1M0 − CVA and hypertension Billroth II 11
10 M 58 30 T1N2M0 + LN metastasis (palliative
gastrectomy) Billroth II 8
11 F 70 30 T1N1M0 + LN metastasis Billroth I 3
12 M 85 30 T1N1M0 + AMI and LN metastasis Billroth II 11
†Abbreviations: TNM: tumor-lymph node-metastasis; HCC: hepatocellular carcinoma; LN: lymph node; CVA: cerebrovascular accident; AMI: acute
myocardial infarction.
In conclusion, the incidence of gastric remnant carcino-
ma has not decreased, detecting gastric remnant carcinoma
early, long-term follow-up, and an appropriate curative re-
section are important for long-term survival after surgery.
As seen in the patients in this study, comorbidities such as
myocardial infarction, cardiac arrhythmia, and uremia must
also be prevented.
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